Escitalopram and Optic atrophy - a phase IV clinical study of FDA data

Summary:

Optic atrophy is reported as a side effect among people who take Escitalopram (escitalopram oxalate), especially for people who are female, 40-49 old, also take Amlodipine, and have Blood pressure abnormal.

The phase IV clinical study analyzes which people have Optic atrophy when taking Escitalopram. It is created by eHealthMe based on reports of 75,134 people who have side effects when taking Escitalopram from the FDA, and is updated regularly.

What is Escitalopram?

Escitalopram has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 78,082 Escitalopram users. Check the latest studies of Escitalopram.

What is Optic atrophy?

Optic atrophy (the loss of a proportion of optic disc nerve fibres) is found to be associated with 242 drugs and 453 conditions by eHealthMe. Check the latest studies of Optic atrophy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

75,134 people reported to have side effects when taking Escitalopram.
Among them, 41 people (0.05%) have Optic atrophy.

Among these 41 people:

What is the gender of people who have Optic atrophy when taking Escitalopram? *

female: 91.43 %
male: 8.57 %

What is the age of people who have Optic atrophy when taking Escitalopram? *

What are other drugs people take besides Escitalopram? *

Amlodipine: 29 people, 70.73%
Insulin: 21 people, 51.22%
Activated Charcoal: 7 people, 17.07%
Epinephrine: 3 people, 7.32%
Risperidone: 3 people, 7.32%
Potassium Chloride: 3 people, 7.32%
Calcium Gluconate: 3 people, 7.32%
Vasopressin: 3 people, 7.32%
Glucagon: 3 people, 7.32%
Norepinephrine Bitartrate: 2 people, 4.88%

What are other side effects people have besides Optic atrophy? *

Pulmonary Oedema (fluid accumulation in the lungs): 35 people, 85.37%
Hypokalemia (low potassium): 35 people, 85.37%
Hypoglycemia (low blood sugar): 35 people, 85.37%
Anuria (failure of the kidneys to produce urine): 34 people, 82.93%
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin): 29 people, 70.73%
Optic Nerve Injury: 28 people, 68.29%
Blindness: 28 people, 68.29%
Arrhythmias (irregular heartbeat): 28 people, 68.29%
Hypotension (abnormally low blood pressure): 28 people, 68.29%
Altered State Of Consciousness (altered state of mind): 27 people, 65.85%

What are the existing conditions these people have? *

Hypokalemia (low potassium): 3 people, 7.32%
Blood Pressure Abnormal: 3 people, 7.32%
Uveitis (inflammation of the uvea): 1 person, 2.44%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 2.44%
Pain: 1 person, 2.44%
Osteoporosis (bones weak and more likely to break): 1 person, 2.44%
Migraine (headache): 1 person, 2.44%
Gastric Ph Decreased: 1 person, 2.44%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 2.44%
Bruxism (habitual grinding of the teeth, typically during sleep): 1 person, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Escitalopram and have Optic atrophy?

- Check whether Optic atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Escitalopram:

Escitalopram (78,082 reports)

Optic atrophy treatments and more:

Optic atrophy (2,242 reports)

Browse all side effects of Escitalopram:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Optic atrophy:

Optic atrophy (242 drugs)

Browse all the conditions that are associated with Optic atrophy:

Optic atrophy (453 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on escitalopram oxalate (the active ingredients of Escitalopram) and Escitalopram (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.